Results 161 to 170 of about 15,233 (264)

Endogenous Amplification of Apoptosis via p53 Regulation using a Cascade Nanocatalytic Medicine

Advanced Science, Volume 13, Issue 19, 2 April 2026.
An engineered MOF nanomedicine (MAL) triggers cascade nanocatalysis in tumors, converting H2O2 and L‐Arg into cytotoxic peroxynitrite. This induces DNA damage, activates the p53 pathway, and amplifies mitochondrial apoptosis via the BAX/Bcl‐2/Caspase‐3 axis, effectively inhibiting colorectal cancer growth with high biocompatibility.
Tan Wu, Xiaoyue Xu, Dan Xu, Hui Zhang, Nan Wang, Yang Yang, Qian Chen, Shunjie Chen, Cheng Li   +8 more
wiley   +1 more source

Periodontitis and extracellular vesicles: Emerging roles in inflammation, tissue destruction and systemic crosstalk

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Extracellular vesicles released from periodontal tissues and pathogens mediate local inflammation and disseminate systemically via the circulation. By transporting regulatory microRNAs and inflammatory cytokines, these vesicles link periodontitis to systemic inflammatory conditions and represent emerging targets for minimally invasive diagnostics and ...
Mai Ahmed, Dada Oluwaseyi Temilola, Mushi Matjila, Manogari Chetty   +3 more
wiley   +1 more source

Poly [ADP-Ribose] Polymerase 1 [PDF]

, 2020
openaire   +1 more source

Clinical Discovery and Molecular Analysis of Two Novel MSH2 Gene Mutations (p.Ala771Gly and p.Val797Gly) in Saudi Colorectal Cancer Patients: Potential Implications for Tumorigenesis

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Colorectal cancer (CRC) is a serious global health problem, ranking first in men and third in women among all cancers worldwide. The genetic basis for CRC remains unclear in most cases; therefore, the present study aimed to investigate the molecular genetic basis of CRC and correlate it with disease outcomes.
Mahmood Rasool, Absarul Haque, Mohammed Alharthi, Tainus Ali, Sajjad Karim, Loubna Siraj Mira, Fahd Al‐Abbasi, Murad Aljiffry, Mohammed Ghunaim, Abdulrahman Sibiany, Peter Natesan Pushparaj   +10 more
wiley   +1 more source

Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-κB in THP-1 monocytes. [PDF]

PLoS One
Mustafa K, Han Y, He D, Wang Y, Niu N, Jose PA, Jiang Y, Kopp JB, Lee H, Qu P.   +9 more
europepmc   +1 more source

Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells. [PDF]

Oncotarget, 2017
Burchett KM, Etekpo A, Batra SK, Yan Y, Ouellette MM.   +4 more
europepmc   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

PARP (poly[ADP-ribose] polymerase) [PDF]

, 2012
openaire   +2 more sources

Poly(ADP-Ribose) Polymerases-Inhibitor Talazoparib Inhibits Muscle Atrophy and Fatty Infiltration in a Tendon Release Infraspinatus Sheep Model: A Pilot Study. [PDF]

Metabolites
Olthof MGL, Hasler A, Valdivieso P, Flück M, Gerber C, Gehrke R, Klein K, von Rechenberg B, Snedeker JG, Wieser K.   +9 more
europepmc   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.
What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source